The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells

The interleukin-6 (IL-6) membrane receptor and its circulating soluble form, sIL-6R, can be targeted by antibody therapy to reduce deleterious immune signaling caused by chronic overexpression of the pro-inflammatory cytokine IL-6. This strategy may also hold promise for treating acute hyperinflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousif, Ashraf S., Ronsard, Larance, Shah, Pankaj, Omatsu, Tatsushi, Sangesland, Maya, Bracamonte Moreno, Thalia, Lam, Evan C., Vrbanac, Vladimir D., Balazs, Alejandro B., Reinecker, Hans-Christian, Lingwood, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836640/
https://www.ncbi.nlm.nih.gov/pubmed/33357409
http://dx.doi.org/10.1016/j.immuni.2020.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836640/
https://www.ncbi.nlm.nih.gov/pubmed/33357409
http://dx.doi.org/10.1016/j.immuni.2020.12.001

Ejemplares similares